Anebulo Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $28.76K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Dec 31, 2025 | Feb 12, 2026 | During market hours | – | $-0.05 | – |
| Q1 FY2026 Ended Sep 30, 2025 | Nov 13, 2025 | During market hours | – | $-0.05 | – |
| Q4 FY2025 Ended Jun 30, 2025 | Sep 29, 2025 | During market hours | – | $-0.05 | – |
| Q3 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Dec 31, 2024 | Feb 14, 2025 | During market hours | – | – | – |
| Q1 FY2025 Ended Sep 30, 2024 | Nov 13, 2024 | During market hours | – | – | – |
| Q4 FY2024 Ended Jun 30, 2024 | Sep 25, 2024 | During market hours | – | – | – |
| Q3 FY2024 Ended Mar 31, 2024 | May 15, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Dec 31, 2023 | Feb 13, 2024 | During market hours | – | – | – |
| Q1 FY2024 Ended Sep 30, 2023 | Nov 14, 2023 | During market hours | – | – | – |
| Q4 FY2023 Ended Jun 30, 2023 | Sep 20, 2023 | During market hours | – | – | – |
| Q3 FY2023 Ended Mar 31, 2023 | May 11, 2023 | Before market open | – | – | – |
Press releases
Announcements Anebulo Pharmaceuticals filed with the SEC
Pharmaceuticals Reports Second Quarter Fiscal Year 2026
Results of operations · EX-99.1 to Form 8-K
Voluntarily Delist from Nasdaq and Deregister with SEC
Listing notice · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Final Results of Tender Offer
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Preliminary Results of Tender Offer
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Other events · EX-99.1 to Form 8-K
Anebulo Pharmaceuticals Reports First Quarter Fiscal
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
Other events · EX-99.1 to Form 8-K
Anebulo Pharmaceuticals Reports Third Quarter Fiscal
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports First Quarter Fiscal Year 2025
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Other events · EX-99.1 to Form 8-K
Pharmaceuticals Reports Third Quarter Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Second Quarter Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports First Quarter Fiscal Year 2024
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023
Results of operations · EX-99.1 to Form 8-K
Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates
Results of operations · EX-99.1 to Form 8-K